2014
Targeting Bruton's tyrosine kinase in B cell malignancies
Publication
Publication
Nature Reviews Cancer , Volume 14 - Issue 4 p. 219- 232
Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies. Small-molecule inhibitors of BTK have shown antitumour activity in animal models and, recently, in clinical studies. High response rates were reported in patients with chronic lymphocytic leukaemia and mantle cell lymphoma. Remarkably, BTK inhibitors have molecular effects that cannot be explained by the classic role of BTK in BCR signalling. In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.
Additional Metadata | |
---|---|
doi.org/10.1038/nrc3702, hdl.handle.net/1765/56478 | |
Nature Reviews Cancer | |
Organisation | Department of Pulmonology |
Hendriks, R., Yuvaraj, S., & Kil, L. (2014). Targeting Bruton's tyrosine kinase in B cell malignancies. Nature Reviews Cancer (Vol. 14, pp. 219–232). doi:10.1038/nrc3702 |